Phaseline

Companies › Vyriad

Vyriad: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VV1
Oncolytic virus expressing interferon-beta
–Phase 2MelanomaDec 2026
VV169
In vivo BCMA-CAR T cell therapy (T-cell targeted lentiviral vector expressing BCMA-directe
TNFRSF17Phase 1Multiple Myeloma RefractoryAug 2027
VSV-IFNβ-NIS
Oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and sodium io
–Phase 1Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03647163VSV-IFNβ-NISPhase 1Solid TumorOncologyJul 2025
NCT04291105VV1Phase 2MelanomaOncologyDec 2026
NCT07802717VV169Phase 1Multiple Myeloma RefractoryOncologyAug 2027

Targets

TNFRSF17 (1)

Companies with the same targets

Johnson & Johnson (Janssen) Regeneron Pharmaceuticals AstraZeneca Pfizer GSK Gracell Biotechnologies (Shanghai) Bristol-Myers Squibb Keymed Biosciences Co.Ltd Chongqing Precision Biotech iCell Gene Therapeutics

Companies built like this

Vividion Therapeutics Tesaro HRYZ Biotech ImmVira Pharma Guangzhou Virotech Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.